We have collected information about Sirna Delivery For The Treatment Of Ovarian Cancer for you. Follow the links to find out details on Sirna Delivery For The Treatment Of Ovarian Cancer.
https://www.sciencedirect.com/science/article/pii/S1046202313000182
Sep 15, 2013 · Together, these data demonstrate that i.p. delivery of formulated siRNA to ovarian cancer can impart significant efficacy in several pre-clinical models. 3.4. Targeted intraperitoneal siRNA delivery. Nanoparticles that are injected i.p can be functionalized with targeting ligands to enhance further the efficiency of siRNA delivery to ovarian cancer.Author: Michael S. Goldberg
https://www.ncbi.nlm.nih.gov/pubmed/23403216
Sep 15, 2013 · Several groups have worked to develop carriers that facilitate siRNA delivery into ovarian cancer cells in mouse models of ovarian cancer. The results have been promising, often leading to significant survival extension. Such benefit is critical for a disease that is characterized by very poor outcomes and demands novel treatment options.Author: Michael S. Goldberg
https://www.sciencedirect.com/science/article/pii/S0169409X09001495
Traditional therapies such as surgery, chemotherapy, and radiation therapy have been used for the treatment of ovarian cancer. Probably due to the lethality of the cancer, in vivo siRNA treatment of ovarian cancer animal models has been intensively studied using various synthetic systems.Author: Yu-Kyoung Oh, Tae Gwan Park
https://www.researchgate.net/publication/235603486_SiRNA_delivery_for_the_treatment_of_ovarian_cancer
Delivery of small interfering RNA (siRNA) is recently gaining tremendous attention for the treatment of ovarian cancer.
https://www.sciencedirect.com/science/article/pii/S0168365918302694
A large diversity of carriers and cargos has been explored for siRNA delivery to ovarian cancer. Nearly all approaches have in common that they incorporate the anionic siRNA via non-covalent complexation with the cationic carrier. Furthermore, the net positive …Author: Dirk van den Brand, Vicky Mertens, Leon F.A.G. Massuger, Roland Brock
https://www.ncbi.nlm.nih.gov/pubmed/30616494
Recently, there have been advances in RNA interference therapy, specifically with small interfering RNA (siRNA), to reduce tumor burden for ovarian cancer via gene down-regulation. However, delivery of siRNA poses its own challenges, as siRNA is unstable in circulation, is unable to be effectively internalized by cells, and may cause toxicity in off-target sites.Author: Christopher Halbur, Niharika Choudhury, Michael Chen, Jun Hyuk Kim, Eun Ji Chung
https://www.nature.com/articles/srep36518
Nov 07, 2016 · A functionalized nanohydrogel siRNA delivery system and a mouse model of serous ovarian cancer were used to test predictions from previous cell line studies that knockdown of EGFR (epidermal growth...Author: Minati Satpathy, Roman Mezencev, Lijuan Wang, John F. McDonald
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628713/
For the treatment of multidrug-resistant lung cancer, the system includes siRNA targeted to MRP1 and BCL2 mRNA, whereas breast and ovarian cancers require siRNA targeted to MDR1 and BCL2 mRNA. The developed system enhanced efficiency of chemotherapy to a level that cannot be achieved by applying any active component separately.Author: Maha Saad, Olga B Garbuzenko, Tamara Minko
https://www.sciencedirect.com/science/article/pii/S1818087614000646
The siRNA-loaded nanoparticles, known as Micelleplex, can be effectively internalized and subsequently release siRNA into cells, resulting in significant gene knockdown activity, which was demonstrated by delivering two siRNAs targeting green fluorescence protein (GFP) that effectively silenced GFP expression in 40–70% of GFP-expressing HEK293 cells . mPEG-b-PCL-b-PPEEA has also been used for acid ceramidase …Author: Cong-fei Xu, Jun Wang
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845562/
This approach will offer a novel systemic siRNA delivery strategy that couples the molecular targeting of cancer cells with the infrared-triggered local release of functional siRNAs for human melanoma cancer therapy. If successful, this GNS-siRNA delivery system will be a major advancement in siRNA delivery technology and tumor-targeted therapy and may have immediate translational applications for systemic treatment …Author: Wei Guo, Wei Guo, Wangbing Chen, Wendan Yu, Wenlin Huang, Wuguo Deng
Searching for Sirna Delivery For The Treatment Of Ovarian Cancer?
You can just click the links above. The data is collected for you.
